Inovio Pharmaceuticals (NASDAQ:INO) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.92 and traded as high as $2.58. Inovio Pharmaceuticals shares last traded at $2.41, with a volume of 976,420 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on INO shares. HC Wainwright restated a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Piper Sandler initiated coverage on Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They issued an “overweight” rating and a $5.00 price objective on the stock. Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Zacks Research lowered Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a report on Saturday, September 27th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.80.

Inovio Pharmaceuticals Trading Down 0.8%

The stock has a fifty day moving average of $2.13 and a 200-day moving average of $1.92. The firm has a market capitalization of $128.07 million, a price-to-earnings ratio of -0.92 and a beta of 1.65.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.02. As a group, equities research analysts forecast that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Nomura Holdings Inc. acquired a new position in Inovio Pharmaceuticals in the 1st quarter worth approximately $28,000. Freedom Investment Management Inc. acquired a new stake in Inovio Pharmaceuticals during the 1st quarter valued at $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares in the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Inovio Pharmaceuticals in the second quarter worth $35,000. Finally, Jane Street Group LLC boosted its position in shares of Inovio Pharmaceuticals by 118.2% in the fourth quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 21,512 shares during the period. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.